Annual report [Section 13 and 15(d), not S-K Item 405]

Share-based Compensation (Tables)

v3.25.1
Share-based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Information about Incentive Plan

The following table contains information about the 2019 Plan as of December 31, 2024:

  

    Awards                 Awards  
    Reserved for     Awards     Awards     Available for  
    Issuance     Issued     Exercised     Grant  
2019 Plan(1)     1,651,429       793,735       149,464       857,594  
Awards issued in excess of 2019 Plan(2)     -       70,623       70,623       -  

 

(1) Includes incentive stock options and restricted stock units discussed below.
   
(2) Includes shares of restricted common stock granted outside of the 2019 Plan to our Chief Executive Officer, Adam Levy.
Schedule of Incentive Stock Option Activity

The following table summarizes the Company’s incentive stock option activity and related information for the year ended December 31, 2024:

   

                Weighted  
          Weighted     Average  
          Average     Contractual  
    Number of     Exercise     Term in  
    Options     Price     Years  
Outstanding at January 1, 2023     524,937     $ 2.351416       8.38  
Granted     117,532     $ 2.06041       10.00  
Exercised     (3,295 )     1.75        
Forfeited                  
Cancelled     (69,854 )     1.965823        
Expired     (8,670 )     1.703222        
Outstanding at December 31, 2023     560,650     $ 2.350742       7.95  
Granted     172,000     $ 2.683140       10.00  
Exercised     (90,860 )     1.006035        
Forfeited                  
Cancelled     (39,107 )     1.006035        
Expired     (14,286 )     5.25        
Outstanding at December 31, 2024     588,397     $ 2.674538       7.81  
Exercisable at December 31, 2024     353,397     $ 2.168073       7.24  
Schedule of Assumptions used in Share-based Compensation

   

    2024     2023  
Volatility     277.56-279.29 %     257.64-258.01 %
Risk-free interest rate     3.44-3.67 %     4.21-4.42 %
Dividend yield     0.0 %     0.0 %
Expected term     5.00 years       5 - 5.50 years  
Schedule of Restricted Stock Units Granted

  

    Number of    

Weighted

Average

Grant Date

 
    Units     Fair Value  
Outstanding at December 31, 2022     90,432     $ 1.43  
Granted     37,037       1.35  
Exercised and converted to common shares     (50,157 )     1.76522  
Forfeited     (12,750 )     1.82  
Outstanding at December 31, 2023     64,562       1.82  
Granted     57,972       2.46  
Exercised and converted to common shares     (62,910 )     2.08  
Forfeited     (3,750 )     2.30  
Outstanding at December 31, 2024     55,874     $ 2.16  
Exercisable at December 31, 2024     2,500     $ 1.82  
Schedule of Common Stock Warrants

The following table shows a summary of common stock warrants for the years ended December 31, 2024 and 2023.

  

          Weighted     Weighted  
          Average     Average  
    Number of     Exercise     Contractual  
    Warrants     Price     Term in Years  
Outstanding at December 31, 2022     3,637,190     $ 5.16281       3.65  
Granted                  
Exercised     (109,720 )     0.55        
Forfeited                  
Cancelled     (84,566 )     0.89        
Expired                  
Outstanding at December 31, 2023     3,442,904       5.414793       2.87  
Warrants – 2021 IPO(1)     387,750       5.50       2.99  
Outstanding at January 1, 2024 (corrected)     3,830,654       5.423418       2.88  
Granted     947,792       4.18       5.00  
Exercised     (5,439 )     2.80        
Forfeited                  
Cancelled     (7,802 )     2.80        
Expired                  
Outstanding at December 31, 2024     4,765,205     $ 5.183120       2.42  
Exercisable at December 31, 2024     4,765,205     $ 5.183120       2.42  

 

  (1) The warrants outstanding have been corrected to reflect 387,750 additional warrants related to the December 27, 2021 unit offering not previously included in the prior year warrant schedule.